Israeli stem cell therapy company Gamida Cell Ltd. has announced success in the Phase III clinical trial of its treatment for leukemia and lymphoma StemEx. The results show a mortality rate which is 35.5 percent lower for people treated with StemEx, as opposed to people who were not.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments